Skip to Content

Generic Corlanor Availability

Corlanor is a brand name of ivabradine, approved by the FDA in the following formulation(s):

CORLANOR (ivabradine hydrochloride - tablet;oral)

  • Manufacturer: AMGEN INC
    Approval date: April 15, 2015
    Strength(s): EQ 5MG BASE, EQ 7.5MG BASE [RLD]

Has a generic version of Corlanor been approved?

No. There is currently no therapeutically equivalent version of Corlanor available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Corlanor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent 7,361,649
    Issued: April 22, 2008
    Inventor(s): Horvath; Stéphane & Auguste; Marie-Noëlle & Damien; Gérard
    Assignee(s): Les Laboratoires Servier
    A β-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
    Patent expiration dates:
    • April 17, 2026
      ✓ 
      Patent use: A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent 7,361,650
    Issued: April 22, 2008
    Inventor(s): Horvath; Stéphane & Auguste; Marie-Noëlle & Damien; Gérard
    Assignee(s): Les Laboratoires Servier
    A γ-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
    Patent expiration dates:
    • April 14, 2026
      ✓ 
      Patent use: A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent 7,867,996
    Issued: January 11, 2011
    Inventor(s): Horvath; Stephane & Auguste; Marie-Noelle & Damien; Gerard
    Assignee(s): Les Laboratories Servier
    A γ-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
    Patent expiration dates:
    • February 22, 2026
      ✓ 
      Patent use: A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
    Patent 7,879,842
    Issued: February 1, 2011
    Inventor(s): Horvath; Stephane & Auguste; Marie-Noelle & Damien; Gerard
    Assignee(s): Les Laboratoires Servier
    β-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as bradycardics.
    Patent expiration dates:
    • February 22, 2026
      ✓ 
      Patent use: A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 15, 2020 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide